Australia markets closed

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
51.82+5.10 (+10.92%)
At close: 04:00PM EDT
51.82 0.00 (0.00%)
Pre-market: 08:16AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close46.72
Open46.69
Bid0.00 x 900
Ask54.00 x 1200
Day's range45.14 - 52.69
52-week range29.10 - 52.69
Volume3,541,480
Avg. volume1,359,819
Market cap4.438B
Beta (5Y monthly)1.14
PE ratio (TTM)N/A
EPS (TTM)-3.21
Earnings date01 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est62.75
  • Zacks

    Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cytokinetics Reports Second Quarter 2022 Financial Results

    Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quar

  • GlobeNewswire

    Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

    New Data Span Ten Years of Clinical Trial Research from Nearly 600 People with ALSSOUTH SAN FRANCISCO, Calif., AND WASHINGTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from Cytokinetics’ completed clinical trials in ALS including, BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improve